Thomas Ton
Internal Medicine · Garden Grove, CANPI 1912018789
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Amgen at 24.9% of the total. Reporting peaked in 2019 at $5,789 and has fallen 68.4% since, to $1,830 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $113.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Gilead$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- AbbVie$1K
- Lilly USA, LLC$990
- plus $4K from 21 others
What the payments were for
- Food & beverage$13,711100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 29 | $3,413 |
| Gilead | 15 | $1,894 |
| AstraZeneca | 10 | $1,104 |
| Boehringer Ingelheim | 10 | $1,074 |
| AbbVie(2 entities) | 9 | $1,053 |
| Lilly USA, LLC | 12 | $990 |
| Johnson & Johnson | 6 | $560 |
| Phathom Pharmaceuticals, Inc. | 4 | $506 |
| Intercept Pharmaceuticals, Inc. | 3 | $353 |
| Inari Medical, Inc. | 2 | $270 |
| Aimmune Therapeutics, Inc. | 2 | $250 |
| Mayne Pharma Commercial LLC | 2 | $246 |
| Novartis | 2 | $244 |
| Amarin Pharma, Inc. | 2 | $235 |
| Abbott | 1 | $159 |
| Sanofi | 1 | $145 |
| Theratechnologies Inc. | 1 | $125 |
| Ardelyx, Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Bayer | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| GSK | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $120 |
| Bard Peripheral Vascular, Inc. | 1 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $110 |
| Merck | 1 | $106 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,711 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alprazolam | 15 | $83 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Garden Grove
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.